General Information
Tucatinib is indicated with trastuzumab and capecitabine for the treatment of adults diagnosed with advanced unresectable or metastatic HER2-positive breast cancer. This includes patients with brain metastases and those who have received one or more prior anti-HER2-based regimens in the metastatic setting.
About the API
Systematic name
6-N-(4,4-dimethyl-5H-1,3-oxazol-2-yl)-4-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine
Trade name(s)
Tukysa
Technology
Synthetic
Molecular Formula
C26H24N8O2
Molecular Weight
480.5 g/mol
Therapeutic category
Oncology
Regulations
US DMF
US DMF